openPR Logo
Press release

Hyperhidrosis Therapeutics Pipeline to Witness Remarkable Growth due to Increased Number of Pipeline Candidates by Drug Developers | Top players are Brickell Biotech, Inc., Medytox Inc., MediTox s.r.o., Allergan, Dermira, Inc., Atacama Therapeutics, Inc.,

06-07-2019 12:22 PM CET | Health & Medicine

Press release from: Pharma Proff

Hyperhidrosis Therapeutics Pipeline to Witness Remarkable

Hyperhidrosis refers to excessive sweating from some body parts, including palms, heads, feet, or underarms. It is mainly categorized into two types: primary hyperhidrosis and secondary hyperhidrosis. It can be diagnosed by physical examinations of the excessively sweating body parts and by conducting a sweat test. The available treatment options for hyperhidrosis include Botulinum toxin, prescription medicines, antiperspirants, and iontophoresis.

Download the sample report at:

Botox injection (Allergan plc) and Qbrexza (Dermira Inc.) are amongst the U.S. Food and Drug Administration (USFDA) approved therapies for hyperhidrosis.

According to the research findings, majority of pipeline drug candidates are being developed for topical administration. It has been observed that the topical route of administration is convenient, less risk of systemic infections, and inexpensive in nature, and also provides improved patient’s compliance. Moreover, the entire administered dose reaches the target glands and immediately starts showing its effects on hyperhidrosis.

Get the detailed analysis at:

Companies that are involved in developing therapeutics for hyperhidrosis have shown positive clinical results in various phases of drug development. For instance, in June 2016, Dermira Inc. announced positive clinical results of phase III trial of DRM04 for the treatment of patients with hyperhidrosis. The results of the study concluded that the primary endpoints were achieved and patients showed statistically significant improvement as compared to placebo.

Make enquiry before purchase at:

Botox injection and Qbrexa are most commonly drugs used for the treatment of hyperhidrosis. These drugs hold significant share in the global hyperhidrosis market. Therefore, with the emergence of late- and mid-stage pipeline products, the overall hyperhidrosis therapeutics market is expected to grow significantly in the upcoming years.

Some of the key players involved in the development of hyperhidrosis therapeutics in the late- and mid-stage include Brickell Biotech Inc., Meditox Co. Ltd., Allergan plc, Dermira Inc., Atacama Therapeutics Inc., Kaken Pharmaceutical Co. Ltd., Revance Therapeutics Inc., HUGEL Inc., Prime Therapeutics LLC, and Roivant Sciences Ltd.

Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455

About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hyperhidrosis Therapeutics Pipeline to Witness Remarkable Growth due to Increased Number of Pipeline Candidates by Drug Developers | Top players are Brickell Biotech, Inc., Medytox Inc., MediTox s.r.o., Allergan, Dermira, Inc., Atacama Therapeutics, Inc., here

News-ID: 1767869 • Views: 721

More Releases from Pharma Proff

Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates. IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6? receptor. This protein is assumed to
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates. Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete
Probiotics Therapeutics -Pipeline Analysis 2018, Clinical Trials & Results, Pate …
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome. Download the sample report at: Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant G …
Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances

All 5 Releases

More Releases for Therapeutics

Digital Therapeutics Market, Digital Therapeutics Market Size, Digital Therapeut …
The global digital therapeutics market is expected to reach US$ 8,941.1 Mn by 2025 from US$ 1,993.2 Mn in 2017. The market is estimated to grow with a CAGR of 20.8% during the forecast period from 2018 to 2025. North America is the largest geographic market and it is expected to be the largest revenue generator during the forecast period, whereas the market is expected to witness growth at a significant
Pruritus Drug Market – Key Players are Cara Therapeutics, Enteris BioPharma, N …
The Pruritus Drug Market research report is a significant investigation of changing business sector elements, driving elements, impediments, and limitations that have been considered the most extensive impacts on market development. Adroit investigative devices, for example, Porter’s Five Forces examination, SWOT examination, and Feasibility examination study have likewise been utilized by the report to offer an exhaustive information of the market. It will go about as a key research report
Dravet Syndrome Therapeutics- Pipeline Analysis 2018 | Zogenix, Inc., Ovid Thera …
Dravet syndrome is a form of severe myoclonic epilepsy that occurs in infants during their first year of age. If left untreated, it can be associated with other types of seizures, and status epilepticus. Children having Dravet syndrome are generally observed with poor cognitive skills and hyperactivity. Download the sample report @ It severely affects the person’s quality of life and around 10-20% of the patient are estimated to die due
Global mRNA Cancer Vaccines and Therapeutics Market to 2025| Moderna Therapeutic …
Researchmoz added Most up-to-date research on "Global mRNA Cancer Vaccines and Therapeutics Market Size, Status and Forecast 2019-2025" to its huge collection of research reports. mRNA Cancer Vaccines and Therapeutics Market report includes (6 Year Forecast 2019-2025) includes Overview, classification, industry value, price, cost and gross profit. It also offers in-intensity insight of the mRNA Cancer Vaccines and Therapeutics industry masking all vital parameters along with, Drivers, Market Trends, Market Dynamics,
Global Pruritus Therapeutics Market Report 2019 Companies included Actavis, Trev …
Market Reports Company has recently published 7th edition of Pruritus Therapeutics Market Report which covers historic data of year 2013 to 2018 along with a forecast till year 2026. For inquiry or free sample pages email us at: The report provides a comprehensive view on the current state and future prospects of the market which analyzes different strategies for business growth. The global Pruritus Therapeutics market was valued at USD xx
MRNA Vaccines & Therapeutics Market 2019 Global Analysis By Key Players – Mode …
WiseGuyReports.Com Publish a New Market Research Report On –“ MRNA Vaccines & Therapeutics Market 2019 Global Analysis By Key Players – Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics”. Description:- The mRNA Vaccines & Therapeutics industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, mRNA Vaccines & Therapeutics market size to maintain the average annual growth rate of XXX from